Last reviewed · How we verify
Exenatide-Bayetta — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Exenatide-Bayetta (Exenatide-Bayetta) — Novo Nordisk A/S.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Exenatide-Bayetta TARGET | Exenatide-Bayetta | Novo Nordisk A/S | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Exenatide-Bayetta CI watch — RSS
- Exenatide-Bayetta CI watch — Atom
- Exenatide-Bayetta CI watch — JSON
- Exenatide-Bayetta alone — RSS
Cite this brief
Drug Landscape (2026). Exenatide-Bayetta — Competitive Intelligence Brief. https://druglandscape.com/ci/exenatide-bayetta. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab